STRATA Skin Sciences

STRATA Skin Sciences, Inc. is a medical technology company in Dermatology and Plastic Surgery. It engages in developing, commercializing and marketing products for the treatment of dermatologic conditions. The firm operates through the following segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. The company was founded by Dina Gutkowicz-Krusin in December 1989 and is headquartered in Horsham, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

STRATA Skin Sciences pursues growth through international expansion and profitability

STRATA Skin Sciences is strategically focusing on increasing revenue per device and expanding internationally to drive growth.
While facing challenges in domestic billings and lower revenue, the company's cost-cutting measures are enhancing profitability.
The company's efforts to optimize operations and drive revenue growth position it well for future success.

STRATA Skin Sciences reports revenue growth and operational improvements in Q2 2024

STRATA Skin Sciences (SSKN) delivered a mixed performance in Q2 2024 with revenue growth, improved operational efficiency, and strategic financing.
The company showcased strengths in equipment revenue growth, expanding customer base, and effective cost management strategies.
Challenges remain in achieving profitability, sustaining growth momentum, and managing operational costs effectively.
Opportunities lie in leveraging marketing efforts, expanding product offerings, exploring new markets, and optimizing operational efficiency for future growth.

STRATA Skin Sciences reports solid Q3 performance with growth opportunities

STRATA Skin Sciences demonstrated solid financial performance in Q3 2024, leveraging improved revenue per XTRAC and cost management.
While facing challenges in device adoption and operating expenses, the company's DTC initiatives and cash position present growth opportunities.
By focusing on enhancing device utilization and investing in innovation, STRATA Skin Sciences can drive future revenue growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Preliminary, unaudited fourth quarter revenues in the range of $6.6 million to $6.8 million  Preliminary, unaudited fourth quarter recurring revenues in the range of $5.0 million to $5.2 million Worldwide installed base increased by 23 placements in the fourth quarter

STRATA Skin Sciences Announces Preliminary Fourth Quarter 2020 Financial Results and Operational Metrics

HORSHAM, Pa., Jan. 06, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the Company will participate in the upcoming H.C. Wainwright BioConnect Virtual Conference.

STRATA Skin Sciences to Participate in the H.C. Wainwright BioConnect Virtual Conference

HORSHAM, Pa., Dec. 28, 2020 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that it has renewed its existing debt with a lower interest one-year cash secured loan facility with Israel Discount Bank of New York, a multinational commercial bank. The new loan is at a fixed interest rate of 1.40% and is due December 30, 2021.

STRATA Skin Sciences, Inc. Announces Successful Renewal of Note Payable

In this article we will check out the progression of hedge fund sentiment towards Strata Skin Sciences, Inc. (NASDAQ:SSKN) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds have access to expert networks and get tips from industry insiders. They also employ numerous Ivy League graduates and MBAs. Like everyone else, hedge funds perform miserably at times, but their consensus picks have historically outperformed the market after risk adjustments.

Where Do Hedge Funds Stand On Strata Skin Sciences, Inc. (SSKN)?

STRATA Skin Sciences, Inc. (SSKN) CEO Dolev Rafaeli on Q3 2020 Results - Earnings Call Transcript

Shares of Strata Skin Sciences (NASDAQ:SSKN) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share fell 33.33% year over year to ($0.04), which were in line with the estimate of ($0.04).

Strata Skin Sciences: Q3 Earnings Insights

HORSHAM, Pa., Nov. 10, 2020 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the quarter ended September 30, 2020.

STRATA Skin Sciences Reports Third Quarter 2020 Financial Results

HORSHAM, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced Dr. Dolev Rafaeli, Chief Executive Officer and Matthew Hill, Chief Financial Officer will participate in the following investor conferences:

STRATA Skin Sciences to Present at Three Upcoming Investor Conferences

HORSHAM, Pa., Nov. 03, 2020 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that it plans to release its third quarter financial results before the market opens on Tuesday, November 10, 2020. Management will hold a conference call to review the financial results and provide a corporate update starting at at 8:30 am Eastern time / 5:30 a.m. Pacific Time on the same day. The conference call will be concurrently webcast.

STRATA Skin Sciences to Report Third Quarter 2020 Financial Results on November 10, 2020

Delivers fastest results with fewest adverse events compared to topical, traditional UV, biologic and systemic therapies  Providing a better solution for I ntegrated H ealth S ystems and Capitation healthcare – managing the patients and reducing costs for chronic skin disease  Up to 97% savings over Biologic drugs

STRATA Skin Sciences' XTRAC® Technology Found to Be Most Effective and Most Economical Treatment for Plaque Psoriasis Compared to Other Therapies

Cigna Now Provides Insurance Coverage of Excimer Laser Therapy for the treatment of Vitiligo Cigna Now Provides Insurance Coverage of Excimer Laser Therapy for the treatment of Vitiligo

STRATA Skin Sciences Announces: Expanding Medical Coverage for Excimer Laser Treatment of Dermatological Conditions, Enlarging Company's Addressable Market

Company expanding global presence and introducing recurring business model in Japan Company expanding global presence and introducing recurring business model in Japan

STRATA Skin Sciences Announces New Recurring Revenue Direct Distribution Contract with JMEC Co., Ltd. in Japan

HORSHAM, Penn., Sept.  08, 2020  (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced Dr. Dolev Rafaeli, Chief Executive Officer will present at the following investor conferences:

STRATA Skin Sciences to Present at Two Upcoming Investor Conferences

STRATA Skin Sciences' (SSKN) CEO Dolev Rafaeli on Q2 2020 Results - Earnings Call Transcript

Shares of Strata Skin Sciences (NASDAQ:SSKN) rose 7.7% in pre-market trading after the company reported Q2 results.

Recap: Strata Skin Sciences Q2 Earnings

Recurring revenue for the second quarter of 2020 was $2.8 million, a 52.1% decrease over second quarter 2019  Total gross margins in the second quarter of 2020 was 48.7%, a 14.9% decrease over second quarter 2019  Global recurring revenue installed base totaled 806 systems at June 30, 2020  Conference call and webcast, today at 8:30 am Eastern Time

STRATA Skin Sciences Reports Second Quarter 2020 Financial Results

HORSHAM, Pa., Aug.  04, 2020  (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, will release second quarter ended June 30, 2020 financial results on Tuesday, August 11th before the market opens. STRATA Skin Sciences President and Chief Executive Officer, Dr. Dolev Rafaeli, and Matthew C. Hill, Chief Financial Officer, will host a conference call at 8:30 am Eastern time to review the Company’s progress.

STRATA Skin Sciences to Host Second Quarter 2020 Financial Results and Business Update Conference Call on August 11

STRATA Skin Sciences's (SSKN) CEO Dr. Dolev Rafaeli on Q1 2020 Results - Earnings Call Transcript

Recurring revenue for the first quarter of 2020 grew 7.3% over first quarter 2019  Total gross margins in the first quarter of 2020 grew 3.8% over first quarter 2019   Global recurring revenue installed base totaled 838 systems at March 31, 2020  Conference call and webcast, today at 8:30 am Eastern Time

STRATA Skin Sciences Reports First Quarter 2020 Financial Results

$2.0 million forgivable loan received  Provides further business update - Initiating the Patient Outreach Program

STRATA Skin Sciences, Inc. Receives Forgivable Loan Under the Paycheck Protection Program

Preliminary unaudited total revenue for the first quarter of 2020 is expected to be in the range of $6.7 and $6.9 million, consistent with guidance previously given  Global recurring revenue installed base totaled 838 systems at March 31, 2020

STRATA Skin Sciences, Inc. Announces Preliminary First Quarter 2020 Revenue and Provides Business Update

92% of participants achieved reduction in mPASI score of 75% or more after receiving Optimal Therapeutic Dose Therapy with the Multi-Micro Dose® diagnostic tip for the treatment of their plaque psoriasis 92% of participants achieved reduction in mPASI score of 75% or more after receiving Optimal Therapeutic Dose Therapy with the Multi-Micro Dose® diagnostic tip for the treatment of their plaque psoriasis

STRATA Skin Sciences, Inc. Announces Study Published in the Journal of Drugs in Dermatology

STRATA Skin Sciences, Inc. (SSKN) Dolev Rafaeli on Q4 2019 Results - Earnings Call Transcript

New features include increased power range, short-hair scalp tip and on-board database to improve patient safety, treatment efficiency and ease-of-use New features include increased power range, short-hair scalp tip and on-board database to improve patient safety, treatment efficiency and ease-of-use

STRATA Skin Sciences, Inc. Receives A 510(k) Clearance For Its XTRAC Momentum 308nm Excimer Laser Platform

Preliminary, unaudited fourth quarter revenues in the range of $8.8 million to $8.85 million

News for STRATA Skin Sciences Stock (SSKN)